Abstract
2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG) is the most frequently used PET radiopharmaceutical in Europe with more than 200 doses administered per week (Meyer et al. 1995). Studies described in the literature were performed with different 2-[18F]FDG preparations, but the preparations do not differ significantly from one another. The differences are insignificant for the purpose of evaluating clinical data.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baudot P, Jaque M, Robin M (1977) Effect of a diazo-polyoxamacroobicyclic complexing agent on the urinary elimination of lead in lead-poisened rats. Toxicol Appl Pharmacol 41: 113–115
Baumann M, Schäfer E, Grein H (1984) Short term studies with the cryptating agent hexaoxa-diaza-bicyclo-hexacosane in rats. Arch Toxicol 55 [Suppl 7]: 427–429
Dowd MT, Chin-Tu C, Wendel MJ, Faulhaber PJ, Cooper MD (1991) Radiation dose to the bladder wall from 2-(l8F) fluoro-2-desoxy-D-glucose in adult humans. J Nucl Med 32: 707–712
European Pharmacopoeia (1996) Radiopharmaceutical preparations, pp 1424–1433
Gallagher BM, Ansari A, Atkins H et al. (1977) Radiopharmaceuticals XXVII. 18F-labeled 2-desoxy-2-fluoro-D-glu-cose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 18: 990–996
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP (1978). Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of 2-Deoxy-2-[18F]fluoro-D-glucose. J Nucl Med 19: 1154–1161
Hamacher K, Coenen HH, Stöcklin G (1986) Efficient stereo-specific synthesis of no-carrier-added 2-[18F] fluoro-2-deoxy-D-glucose using aminopolyether supported nu-cleophilic substitution. J Nucl Med 27: 235–238
Mejia AA, Nakamura T, Mastoshi I, Hatazawa J, Masaki M, Shoichi W (1991) Estimation of absorbed doses in humans due to intravenous administration of fluorine-18F-fluorodeoxyglucose in PET studies. J Nucl Med 32: 699–706
Meyer G-J, Coenen HH, Waters SL et al. (1993) Quality assurance and quality control of short-lived radiopharma-ceutikals for PET. In: Stöcklin and Pike (eds) Radiopharmaceuticals for PET. Kluwer, Amsterdam, pp 91–150
Meyer GJ, Waters SL, Coenen H H., Luxen A, Maziere B, Langström B (1995) PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur J Nucl Med 22/12: 1420–1432
Oehr P, Ruhlmann J, Rink H (1989) 18F-FDG Transport: Abhängigkeit von Glucosekonzentration und Strahlendosis. Nuklearmedizin 37: A68
Reivich M, Kuhl D, Wolf A et al. (1979). The [18F] fluorodeox-yglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44: 127–137
Som P, Atkins HL, Bandoypadhyay D, Fowler JS et al. (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glu-cose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21: 670–675
United States Pharmacopeia, USP (1995) Fludeoxyglucose F18 Injections. USP 23: 674
Woosley RL, Kim YS, Huang KC (1970) Renal tubular transport of 2-deoxy-D-glucose in dogs and rats. J Pharmacol Exp Ther 173: 13–20
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ruhlmann, J., Oehr, P. (1999). Radiopharmaceutical Technology, Toxicity and Radiation Dosages. In: Ruhlmann, J., Oehr, P., Biersack, HJ. (eds) PET in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60010-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-60010-4_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64220-3
Online ISBN: 978-3-642-60010-4
eBook Packages: Springer Book Archive